Inter- and Intra-Observer Agreement of PD-L1 SP142 Scoring in Breast Carcinoma-A Large Multi-Institutional International Study

被引:5
|
作者
Zaakouk, Mohamed [1 ,2 ]
Van Bockstal, Mieke [3 ,4 ]
Galant, Christine [3 ,4 ]
Callagy, Grace [5 ]
Provenzano, Elena [6 ,7 ,8 ]
Hunt, Roger [9 ]
D'Arrigo, Corrado [10 ]
Badr, Nahla M. [1 ,11 ]
O'Sullivan, Brendan [12 ]
Starczynski, Jane [13 ]
Tanchel, Bruce [13 ]
Mir, Yasmeen [14 ]
Lewis, Paul [15 ]
Shaaban, Abeer M. [1 ,12 ]
机构
[1] Univ Birmingham, Inst Canc & Genom Sci, Birmingham B15 2TT, England
[2] Cairo Univ, Canc Pathol, Natl Canc Inst, Cairo 12613, Egypt
[3] Clin Univ St Luc Bruxelles, Dept Pathol, B-1200 Brussels, Belgium
[4] Catholic Univ Louvain, Inst Rech Experimentale & Clin, B-1348 Brussels, Belgium
[5] Univ Galway, Lambe Inst Translat Res, Sch Med, Discipline Pathol, Galway H91 TK33, Ireland
[6] NIHR Cambridge Biomed Res Ctr, Cambridge CB2 0QQ, England
[7] Addenbrookes Hosp, Cambridge CB2 0QQ, England
[8] Cambridge Univ NHS Fdn Trust, Dept Histopathol, Cambridge CB2 0QQ, England
[9] Wythenshawe Hosp, Dept Histopathol, Manchester M23 9LT, England
[10] Poundbury Canc Inst, Dorchester DT1 3BJ, England
[11] Menoufia Univ, Fac Med, Dept Pathol, Shibin Al Kawm 32952, Egypt
[12] Queen Elizabeth Hosp Birmingham, Cellular Pathol, Birmingham B15 2GW, England
[13] Heart England NHS Fdn Trust, Cellular Pathol, Birmingham B9 5ST, England
[14] Royal Liverpool & Broadgreen Univ Hosp, Pathol, Liverpool L7 8YE, England
[15] Swansea Univ, Med Sch, Singleton Pk, Swansea SA2 8PP, Wales
关键词
PD-L1; breast cancer; VENTANA SP142; triple-negative; LIGAND; 1; IMMUNOHISTOCHEMISTRY; CONCORDANCE; ASSAYS;
D O I
10.3390/cancers15051511
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary PD-L1 analysis in TNBC is essential for selecting patients eligible for immunotherapy. Limited data are available on pathologists' concordance regarding PD-L1 assessment. Twelve pathologists of various expertise from three European countries digitally analysed 100 breast cancer core biopsies stained using the SP142 PD-L1 assay in two rounds. The overall inter-observer agreement among the pathologists was substantial. The intra-observer agreement was substantial to almost perfect. The expert scorers were more concordant in evaluating staining percentage compared with those of the non-experts. Challenging cases around the 1% cut-off value for positivity were identified and represented a small 6-8%) proportion of all cases. The experts were more concordant in scoring those cases. The study shows reassuringly strong inter- and intra-observer concordance among pathologists in PD-L1 scoring. A proportion of low-expressors remain challenging to assess, and these would benefit from addressing the technical issues, testing a different sample and/or referring for expert opinions. The assessment of PD-L1 expression in TNBC is a prerequisite for selecting patients for immunotherapy. The accurate assessment of PD-L1 is pivotal, but the data suggest poor reproducibility. A total of 100 core biopsies were stained using the VENTANA Roche SP142 assay, scanned and scored by 12 pathologists. Absolute agreement, consensus scoring, Cohen's Kappa and intraclass correlation coefficient (ICC) were assessed. A second scoring round after a washout period to assess intra-observer agreement was carried out. Absolute agreement occurred in 52% and 60% of cases in the first and second round, respectively. Overall agreement was substantial (Kappa 0.654-0.655) and higher for expert pathologists, particularly on scoring TNBC (6.00 vs. 0.568 in the second round). The intra-observer agreement was substantial to almost perfect (Kappa: 0.667-0.956), regardless of PD-L1 scoring experience. The expert scorers were more concordant in evaluating staining percentage compared with the non-experienced scorers (R-2 = 0.920 vs. 0.890). Discordance predominantly occurred in low-expressing cases around the 1% value. Some technical reasons contributed to the discordance. The study shows reassuringly strong inter- and intra-observer concordance among pathologists in PD-L1 scoring. A proportion of low-expressors remain challenging to assess, and these would benefit from addressing the technical issues, testing a different sample and/or referring for expert opinions.
引用
收藏
页数:17
相关论文
共 43 条
  • [1] SP142 immunohistochemistry (IHC) PD-L1 inter- and intra-pathologist agreement in triple negative breast carcinoma (TNBC)
    Pang, J-M.
    Castles, B.
    Byrne, D. J.
    Button, P.
    Lakhani, S.
    Sivasubramaniam, V.
    Cooper, W.
    Armes, J.
    Millar, E.
    Raymond, W.
    Roberts-Thomson, S.
    Kumar, B.
    Burr, M. L.
    Selinger, C.
    Harvey, K.
    Chan, C.
    Beith, J.
    O'Toole, S. A.
    Fox, S. B.
    ANNALS OF ONCOLOGY, 2020, 31 : S361 - S361
  • [2] Inter- and Intra-observer Agreement of PD-L1 Scoring in Hypopharyngeal Squamous Cell Carcinoma (HSCC), Urothelial Carcinoma (UC), and Breast Carcinoma (BC)
    Downes, Michelle
    Slodkowska, Elzbieta
    Katabi, Nora
    Jungbluth, Achim
    Xu, Bin
    MODERN PATHOLOGY, 2019, 32
  • [3] Inter- and Intra-observer Agreement of PD-L1 Scoring in Hypopharyngeal Squamous Cell Carcinoma (HSCC), Urothelial Carcinoma (UC), and Breast Carcinoma (BC)
    Downes, Michelle
    Slodkowska, Elzbieta
    Katabi, Nora
    Jungbluth, Achim
    Xu, Bin
    LABORATORY INVESTIGATION, 2019, 99
  • [4] Interobserver Variation of PD-L1 (SP142) Immunohistochemistry Interpretation in Breast Carcinoma
    Hoda, Raza
    Brogi, Edi
    D'Alfonso, Timothy
    Grabenstetter, Anne
    Giri, Dilip
    Hanna, Matthew
    Kuba, M. Gabriela
    Murray, Melissa
    Vallejo, Christina
    Zhang, Hong
    Reis-Filho, Jorge
    Wen, Hannah
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 173 - 175
  • [5] Interobserver Variation of PD-L1 (SP142) Immunohistochemistry Interpretation in Breast Carcinoma
    Hoda, Raza
    Brogi, Edi
    D'Alfonso, Timothy
    Grabenstetter, Anne
    Giri, Dilip
    Hanna, Matthew
    Kuba, M. Gabriela
    Murray, Melissa
    Vallejo, Christina
    Zhang, Hong
    Reis-Filho, Jorge
    Wen, Hannah
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 173 - 175
  • [6] Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma
    Hoda, Raza S.
    Brogi, Edi
    D'Alfonso, Timothy M.
    Grabenstetter, Anne
    Giri, Dilip
    Hanna, Matthew G.
    Kuba, M. Gabriela
    Murray, Melissa P.
    Vallejo, Christina E.
    Zhang, Hong
    Reis-Filho, Jorge S.
    Wen, Hannah Y.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2021, 145 (09) : 1132 - 1137
  • [7] PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays
    Grabenstetter, Anne
    Jungbluth, Achim A.
    Frosina, Denise
    Hoda, Raza
    Dos Anjos, Carlos H.
    Patil, Sujata
    Sevilimedu, Varadan
    Weigelt, Britta
    Reis-Filho, Jorge S.
    Zhang, Hong
    Traina, Tiffany
    Robson, Mark E.
    Brogi, Edi
    Wen, Hannah Y.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2021, 45 (09) : 1274 - 1281
  • [8] Collaborative Multi-institutional Experience in Comparing PD-L1 Immunohistochemistry Assays: Concordance of SP142 and 22C3 Immunoreactivity
    Karim, Lina Abdul
    Kallakury, Bhaskar V. S.
    Chahine, Joeffrey J.
    Sheehan, Christine E.
    Ross, Jeffrey S.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2018, 26 (02) : E22 - E22
  • [9] SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3
    Pang, Jia-Min B.
    Castles, Belinda
    Byrne, David J.
    Button, Peter
    Hendry, Shona
    Lakhani, Sunil R.
    Sivasubramaniam, Vanathi
    Cooper, Wendy A.
    Armes, Jane
    Millar, Ewan K. A.
    Raymond, Wendy
    Roberts-Thomson, Samuel
    Kumar, Beena
    Burr, Marian
    Selinger, Christina
    Harvey, Kate
    Chan, Charles
    Beith, Jane
    Clouston, David
    O'Toole, Sandra A.
    Fox, Stephen B.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2021, 45 (08) : 1108 - 1117
  • [10] Study on the heterogeneity of expression of PD-L1 (Ventana SP142) in breast cancer in space and time
    He, J.
    Liu, Y.
    VIRCHOWS ARCHIV, 2021, 479 (SUPPL 1) : S70 - S70